Overview Request Sample Pages Request Customization Download PDF
You are viewing: Europe Preimplantation Genetic Testing Market analysis

The Europe Preimplantation Genetic Testing Market was valued at $124.1 Million in 2025 and projected to reach to $211.4 Million by 2030, representing a compound annual growth rate of 11.2%. Europe's preimplantation genetic testing market is poised for sustained expansion driven by advancing reproductive healthcare infrastructure and increasing clinical adoption of genetic screening technologies.

Europe Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Europe Preimplantation Genetic Testing Market Trends and Insights

  • This growth trajectory reflects Europe's advancing reproductive healthcare infrastructure and increasing adoption of genetic screening technologies among fertility clinics.
  • Europe's regulatory frameworks and reimbursement policies are driving demand for PGT services across major markets including the United Kingdom, Germany, France, and Spain. The European market benefits from high awareness of genetic disorders, strong healthcare spending, and supportive legislation regarding assisted reproductive technologies.
  • Europe's aging population and rising infertility rates are compelling factors driving couples toward PGT solutions.
  • Between 2025 and 2030, Europe is expected to maintain its position as a leading regional market, with the 11.2% CAGR outpacing global growth trends and reflecting sustained investment in fertility innovation across the continent..

Key Market Statistics

  • CAGR (2025-2030) 11.2% CAGR
  • Market Size, 2025 ~USD 124.1 Million
  • Forecast, 2030 ~USD 211.4 Million
  • Geography Europe

Europe Preimplantation Genetic Testing Market Overview

Market Valuation & Growth :

Europe's preimplantation genetic testing market is valued at $124.1 million in 2025, with a robust CAGR of 11.2% projected through 2030, reaching $211.4 million. This growth outpaces the global CAGR of 10.5%, positioning Europe as a high-growth region.

Regulatory & Reimbursement Drivers :

Europe's advanced regulatory frameworks and favorable reimbursement policies are accelerating market adoption. Established healthcare infrastructure and standardized genetic screening protocols across EU member states support widespread implementation of PGT technologies.

Fertility Clinic Adoption :

Increasing adoption of genetic screening technologies among European fertility clinics reflects growing patient demand and clinical confidence in PGT outcomes. Major fertility centers across Germany, UK, and France are integrating PGT into standard reproductive protocols.

Regional Market Leadership :

Germany leads Europe with $79.2 million in market size, followed by the UK at $62.8 million and France at $32.5 million. These markets demonstrate strong healthcare investment and high awareness of genetic testing benefits among reproductive specialists.

Europe Preimplantation Genetic Testing Market Dynamics

  • Favorable regulatory environments across EU member states, combined with growing reimbursement coverage, are facilitating market penetration among fertility clinics and reproductive centers.
  • The region's emphasis on precision medicine and patient safety standards continues to elevate PGT utilization rates. Looking ahead to 2030, Europe's market growth will be supported by technological innovations, rising awareness among patients and healthcare providers, and expanding access to PGT services beyond major metropolitan centers.
  • Continued investment in fertility healthcare infrastructure and evolving clinical guidelines endorsing genetic screening will further strengthen market dynamics across the continent..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • Europe's PGT market will grow from $124.1M (2025) to $211.4M (2030) at an 11.2% CAGR, outpacing global growth.
      • Europe's regulatory support and reimbursement policies create favorable conditions for PGT adoption across fertility clinics.
      • Rising infertility rates and aging populations in Europe are key drivers of increased genetic screening demand.
      • Europe's advanced healthcare infrastructure positions it as a leading regional market for preimplantation genetic testing innovation.

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      Europe Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      DIAGNOSTIC LABORATORIES8.79.510.411.512.714.215.917.811.4
      FERTILITY CLINICS24.926.829.232.135.439.343.748.810.8
      HOSPITALS6.36.77.27.98.69.510.411.59.8
      OTHER END USERS2.32.42.62.83.13.33.649
      TOTAL42.245.449.354.259.866.273.682.110.7

      EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      DIAGNOSTIC LABORATORIES32.134.838.242.34752.658.966.211.6
      FERTILITY CLINICS91.598.8107.7118.7131.3145.8162.6181.711
      HOSPITALS2324.626.62931.83538.642.810
      OTHER END USERS8.79.31010.811.812.914.115.59.2
      TOTAL155.3167.5182.4200.8221.9246.3274.2306.310.9

      Target Audience

      • Fertility Clinic Operators : Clinic managers and reproductive specialists need market intelligence to evaluate PGT service expansion, understand competitive positioning, and identify reimbursement opportunities across European markets.
      • Diagnostic & Testing Companies : PGT service providers and genetic testing laboratories require regional market data to guide product launches, pricing strategies, and partnership development across Europe's diverse healthcare systems.
      • Healthcare Investors & PE Firms : Investment professionals evaluating reproductive healthcare opportunities need comprehensive market analysis to assess growth potential, identify acquisition targets, and evaluate regional expansion strategies in Europe.
      • Medical Device & Biotech Manufacturers : Companies developing PGT technologies and related equipment need market insights to understand adoption rates, regulatory requirements, and commercial opportunities across European fertility centers.
      • Healthcare Policy & Regulatory Bodies : Government agencies and healthcare authorities require market data to inform reimbursement policies, clinical guidelines, and regulatory frameworks governing PGT services across European jurisdictions.

      Key Companies in the Europe Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      Europe vs. other regions

      HowEurope compares to the other 3 regional blocs covered in this market.

      North America
      ~USD 350 Million · 10.1% wtd CAGR ·
      Asia Pacific
      ~USD 170.3 Million · 12.4% wtd CAGR ·
      Latin America
      ~USD 29.5 Million · 9.4% wtd CAGR ·
      Middle East
      ~USD 14.8 Million · 8.8% wtd CAGR ·

      Countries within Europe - compare and drill down

      Country2025 size (native)
      GermanyUSD 79.2 Million
      UKUSD 62.8 Million
      FranceUSD 32.5 Million
      ItalyUSD 14.3 Million
      SpainUSD 9.9 Million
      Rest Of EuropeUSD 56.7 Million

      Country market size visualization

      Germany
      USD 79.2 Million
      UK
      USD 62.8 Million
      France
      USD 32.5 Million
      Italy
      USD 14.3 Million
      Spain
      USD 9.9 Million
      Rest Of Europe
      USD 56.7 Million

      Reasons to Buy this Report

      • Country-Level Market Insights : Detailed market sizing and forecasts for Germany, UK, France, Italy, Spain, and Rest of Europe. Understand regional variations in market maturity, adoption rates, and growth trajectories to identify high-potential markets.
      • Regulatory & Reimbursement Analysis : Comprehensive assessment of Europe's regulatory frameworks and reimbursement policies driving PGT adoption. Identify opportunities and barriers across different EU jurisdictions to inform market entry and expansion strategies.
      • Competitive Landscape Mapping : Strategic analysis of key players and market dynamics specific to Europe. Understand competitive positioning, technology adoption rates, and partnership opportunities among European fertility clinics and diagnostic providers.
      • Growth Opportunity Identification : Pinpoint emerging markets and underserved regions within Europe experiencing accelerated PGT adoption. Leverage insights on clinical adoption trends and patient demand patterns to guide investment and expansion decisions.
      • Strategic Decision Support : Data-driven insights to support market entry, product development, and partnership strategies tailored to European market conditions. Benchmark performance against regional competitors and identify differentiation opportunities.

      Frequently asked questions

      What is the current size of Europe's preimplantation genetic testing market?

      Europe's PGT market was valued at $124.1 million in 2025 and is expected to grow to $211.4 million by 2030.

      What is the projected growth rate for Europe's PGT market?

      Europe's preimplantation genetic testing market is projected to grow at a compound annual growth rate (CAGR) of 11.2% from 2025 to 2030.

      Which European countries are driving PGT market growth?

      Major European markets including the United Kingdom, Germany, France, and Spain are leading drivers of PGT adoption and market expansion across the continent.

      What factors are contributing to Europe's PGT market growth?

      Europe's PGT market growth is driven by regulatory support, reimbursement policies, rising infertility rates, aging populations, and advanced healthcare infrastructure.

      How does Europe's PGT market growth compare to global trends?

      Europe's 11.2% CAGR outpaces the global market growth rate of 10.5%, reflecting stronger regional demand and investment in genetic screening technologies.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status